Medizinische Universität Graz - Research portal

Navigation/Search

• Researchers.
  • Curriculum.
  • Publications.
  • Projects.
  • Presentations.
• Institutions.
• Projects.
• Publications.
• Partners.
• Sponsors.
• Equipment.
• Knowhow.
• Fields of Research.

Rinnerthaler Gabriel |

Presentations at scientific and public conferences

Breitenstein, U; Wrobel, D; Guth, D; Zaiss, M; Terhaag, J; Zahn, MO; Perlova-Griff, L; Distelrath, A; Wuerstlein, R; Apel, K; Deuerling, N; Vannier, C; Bartsch, R; Jackisch, C; Mueller, V; Schmidt, M; Balic, M; Rinnerthaler, G; Lueftner, D; Zaman, K; Schwitter, M; Harbeck, N Extended adjuvant (adj) neratinib in HER2+/HR+ early breast cancer (eBC) in clinical routine - interim analysis of the multinational, prospective, non-interventional study (NIS) ELEANOR (n=300)
BREAST. 2025; 80: 103911 Doi: 10.1016/j.breast.2025.103911
Web of Science FullText FullText_MUG

 

Dobri, N; Dandachi, N; Klocker, EV; Suppan, C; Graf, R; Lazzeri, I; Albertini, C; Rinnerthaler, G; Starzer, AM; Bartsch, R; Hasenleithner, SO; Jost, PJ; Heitzer, E; Balic, M Circulating tumor DNA profiling of patients with metastatic luminal HER2-low and HER2-0 breast cancer via next-generation sequencing.
J CLIN ONCOL. 2025; 43(16_SUPPL):e13090-e13090.-ASCO Annual Meeting I; MAY 30-JUN 3, 2025; Chicago, US. Doi: 10.1200/JCO.2025.43.16_suppl.e13090 [Poster]
Web of Science FullText FullText_MUG

 

Dobric, N; Suppan, C; Klocker, EV; Esterl, T; Moser, T; Hasenleithner, S; Beichler, C; Graf, R; Glawitsch, L; Weiss, L; Sandholzer, M; Steger, GG; Rinnerthaler, G; Heitzer, E; Jost, PJ; Balic, M; Dandachi, N Pathogenic ESR1 alterations and co-alterations in HR+/HER2-advanced breast cancer
ANN ONCOL. 2025; 36: -ESMO Congress 2025; OCT 17-21, 2025; Berlin, GERMANY. Doi: 10.1016/j.annonc.2025.08.934 [Poster]
Web of Science FullText FullText_MUG

 

Filipits, M; Hlauschek, D; Zhang,J; Balic, M; Kates, R; Greil, R;Fitzal, F; Toro-Bauer, N; Rinnerthaler, G; Pinckaers, H; Sotlar, K; Bago-Horvath, Z; Hulla, W; Regitnig, P; Piehler, A; Geyer, CE; Kreipe, H; Griffin, J; Harbeck, N; Wolmark, N; Gnant, M Independent Validation of a Pathology-Based Multimodal Artificial Intelligence Biomarker for Predicting Risk of Distant Metastasis in Postmenopausal, Estrogen Receptor-Positive, Early-Stage Breast Cancer Patients: Analysis of the ABCSG Trial 8
PS3-04-08. 2025; -San Antonio Breast Cancer Symposium; DEC 9-12, 2025; San Antonio, USA. [Poster]
FullText

 

Lax, S; Markowski, K; Manzo, VAM; Tomazic, SB; Suppan, C; Pristauz-Telsnigg, G; Siebenhofer, C; Scheiber, O; Rinnerthaler, G Real-world experience with the 70 gene assay for treatment decisions in ER+/HER2-invasive breast cancer
VIRCHOWS ARCH. 2025; 487: S71-S72.
Web of Science

 

Lüftner, DI; Bartsch, R; Breitenstein, U; Jackisch, C; Mueller, V; Schmidt, M; Balic, M; Rinnerthaler, G; Zaman, K; Schwitter, M; Wrobel, D; Guth, D; Zaiss, M; Terhaag, J; Perlova-Griff, L; Wuerstlein, R; Schinköthe, T; Vannier, C; Harbeck, N Extended adjuvant neratinib in HER2+/HR+ early breast cancer in clinical routine: Final results from the multinational, prospective, observational study ELEANOR
ANN ONCOL. 2025; 36: Doi: 10.1016/j.annonc.2025.08.728
Web of Science FullText FullText_MUG

 

Tomazic, SB; Scheiber, O; Kriegl, D; Hauser, H; Suppan, C; Rinnerthaler, G; Lax, S Different HER2 immunoreactivity in biopsies compared to corresponding surgical specimens of invasive breast carcinomas with potential therapeutic implications
VIRCHOWS ARCH. 2025; 487: S23-S23.
Web of Science

 

Zaman, K; Lüftner, D; Harbeck, N; Breitenstein, U; Jackisch, C; Müller, V; Schmidt, M; Balic, M; Rinnerthaler, G; Schwitter, M; Wrobel, D; Guth, D; Zaiss, M; Terhaag, J; Perlova-Grif, L; Distelrath, A; Deuerling, N; Würstlein, R; Schinköthe, T; Vannier, C; Bartsch, R Extended adjuvant neratinib in HER2+/HR+ early breast cancer in clinical routine-final results from the multinational, prospective, observational study ELEANOR
ONCOL RES TREAT. 2025; 48(SUPPL 2):
Web of Science

 

Beheshti, M; Rinnerthaler, G; Farbod, A; Hitzl, W; Egle, D; Gampenrieder, SP; Bartsch, R; Balic, M; Greil, R; Gnant, M; Pirich, C Predictive role of baseline ^[18F]FDG PET/CT quantitative parameters for response to neoadjuvant treatment with atezolizumab, trastuzumab, pertuzumab and epirubicin in HER2-positive early breast cancer - a substudy of the ABCSG-52/ATHENE phase II trial
EUR J NUCL MED MOL I. 2024; 51: S481-S482. [Poster]
Web of Science

 

↑ Top of page / Navigation

© Med Uni Graz • Imprint